Braf V600e
The most common cancer-driving mutation in the BRAF gene, targeted by several approved drugs.
If Braf V600e is on your watch list: what changed in the coverage, what the reporting asserts, and what the crowd is pricing.
What’s changed
- CDK9 inhibition sensitizes intrinsically resistant BRAF V600E mutant colorectal cancer to BRAF inhibitors. · Acta Pharm Sin B · 2026-05-18
- Successful Encorafenib and Cetuximab Re-Challenge Combined With Nivolumab in BRAF V600E Mutated, Mismatch-Repair-Proficient Metastatic Colorectal Cancer – A Cas · Clinical Colorectal Cancer · 2026-07-26
- A randomised study of encorafenib, cetuximab, and FOLFIRI versus FOLFIRI with or without bevacizumab in BRAF V600E-mutant colorectal cancer: BREAKWATER Cohort 3 · Annals of Oncology · 2026-07-26
- A pathway-dependency framework for acquired resistance to targeted therapy in EGFR-mutant, KRAS G12C-mutant, and BRAF V600E-mutant NSCLC. · Pharmacol Res · 2026-08-06